Abstract
Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cells in vivo. Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.
Original language | English (US) |
---|---|
Article number | e1238558 |
Journal | OncoImmunology |
Volume | 5 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2016 |
Keywords
- Antitumor immunity
- Dectin-1
- dentritic cells
- Th9
- Vaccine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology